Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction
Authors:
- Jan Paul OttervangerJOJan Paul Ottervanger
- Menko-Jan De BoerMBMenko-Jan De Boer
- Jan-Henk E DambrinkJDJan-Henk E Dambrink
- Jan C A HoorntjeJHJan C A Hoorntje
- A T Marcel GosselinkAGA T Marcel Gosselink
- Felix ZijlstraFZFelix Zijlstra
- Harry SuryapranataHSHarry Suryapranata
- Arnoud W J Van 'T HofAHArnoud W J Van 'T Hof
- Zwolle Myocardial Infarction Study GroupZGZwolle Myocardial Infarction Study Group
- 1 September 2009
- journal article
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 20 (6) , 415-421
Abstract
Predictors of 30-day mortality may differ from predictors of mortality at 1 year among 30-day survivors of ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). We aimed to evaluate the predictors of 30-day and 1-year mortality in unselected patients with STEMI treated with PCI. Individual patient data from 4732 patients with STEMI, who were treated with primary PCI during an 11-year study period, were recorded prospectively. Patient characteristics, 30-day, and 1-year outcome were evaluated. At 30-day follow-up, 219 patients (4.6%) died; and out of the 4513 30-day survivors, 109 patients (2.8%) died at 1 year. Patients who died were older, had a higher risk profile. Higher rates of Killip class greater than 2 on admission, multivessel disease, and, more often, lower left ventricular ejection fraction were observed in patients who died. Mortality rate was 7.6% at 30 days among the females when compared with 3.7 among the males, P value less than 0.001. Age and sex-adjusted multivariate analysis revealed that previous myocardial infarction, diabetes, Killip class greater than 2, post-PCI thrombolysis in myocardial infarction flow less than 3, and left ventricular ejection fraction less than 30% were strong predictors of both 30-day and 1-year mortality. However, multivessel disease, anterior myocardial infarct location and in-hospital reinfarction, ischemic time, and pre-PCI thrombolysis in myocardial infarction flow less than 3 were particularly strong predictors of 30-day mortality. Despite the fact that most characteristics of 30-day and 1-year mortality among 30-day survivors are similar, we found that variables that affect mortality beyond the acute phase may not necessarily be the same as those that influence early mortality.Keywords
This publication has 40 references indexed in Scilit:
- Prediction of One-Year Mortality Among 30-Day Survivors After Primary Percutaneous Coronary InterventionsThe American Journal of Cardiology, 2006
- Accuracy of commercially available processing algorithms for planar radionuclide ventriculography using data for a dynamic left ventricular phantomNuclear Medicine Communications, 2004
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003
- Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyThe Lancet, 1997
- Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- Adjunctive Drug Therapy of Acute Myocardial Infarction — Evidence from Clinical TrialsNew England Journal of Medicine, 1996
- Angiographic findings and catheterization laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarctionEuropean Heart Journal, 1995
- A Comparison of Immediate Coronary Angioplasty with Intravenous Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1992